SC
KROS icon

Steven Cohen’s Keros Therapeutics KROS Stock Holding History

Steven Cohen’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Sell
10,393
-98,622
-90% -$1.1M ﹤0.01% 3680
2026
Q1 		$1.2M Buy
109,015
+70,167
+181% +$1.08M ﹤0.01% 2641
2025
Q4 		$791K Buy
+38,848
New +$682K ﹤0.01% 2998
2025
Q2 		– Sell
-6
Closed -$59 – 2422
2025
Q1 		$59 Sell
6
-1,586
-100% -$18.4K ﹤0.01% 1984
2024
Q4 		$25.2K Sell
1,592
-945,978
-100% -$49.2M ﹤0.01% 2018
2024
Q3 		$55M Buy
947,570
+577,220
+156% +$28.5M 0.14% 170
2024
Q2 		$16.9M Sell
370,350
-601,531
-62% -$32.3M 0.04% 445
2024
Q1 		$64.3M Buy
971,881
+890,651
+1,096% +$52.8M 0.16% 140
2023
Q4 		$3.23M Sell
81,230
-68,503
-46% -$2.15M 0.01% 1064
2023
Q3 		$4.77M Sell
149,733
-199,927
-57% -$7.46M 0.01% 893
2023
Q2 		$14M Buy
349,660
+144,000
+70% +$6.31M 0.04% 492
2023
Q1 		$8.78M Sell
205,660
-314,876
-60% -$15.9M 0.03% 581
2022
Q4 		$25M Buy
520,536
+428,696
+467% +$20M 0.09% 283
2022
Q3 		$3.46M Buy
+91,840
New +$3.18M 0.01% 821
2022
Q1 		– Sell
-63,028
Closed -$3.69M – 1285
2021
Q4 		$3.69M Sell
63,028
-85,572
-58% -$4.27M 0.01% 734
2021
Q3 		$5.88M Sell
148,600
-254,007
-63% -$9.04M 0.03% 628
2021
Q2 		$17.1M Buy
402,607
+179,445
+80% +$9.72M 0.08% 321
2021
Q1 		$13.7M Buy
223,162
+9,362
+4% +$593K 0.06% 349
2020
Q4 		$15.1M Buy
213,800
+133,000
+165% +$8.38M 0.07% 346
2020
Q3 		$3.12M Sell
80,800
-71,500
-47% -$2.84M 0.02% 645
2020
Q2 		$5.71M Buy
+152,300
New +$4.69M 0.04% 457

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Steven Cohen's KROS Position: Q2 2026 in Review

Steven Cohen reduced its Keros Therapeutics (KROS) stake by 90% in Q2 2026, selling an estimated $1.1M and leaving 10,393 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #3680.

Steven Cohen first reported a position in KROS in Q2 2020 and has held it in 21 quarters since. The position peaked at $64.3M in Q1 2024. 131 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Steven Cohen held 10,393 shares of Keros Therapeutics worth $111K as of Q2 2026.
  • Steven Cohen sold 98,622 Keros Therapeutics shares in Q2 2026, an estimated $1.1M.
  • Keros Therapeutics made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #3680 holding.
  • Steven Cohen first reported a position in Keros Therapeutics in Q2 2020 and has held it in 21 quarters since.
  • Steven Cohen's Keros Therapeutics position peaked at $64.3M in Q1 2024.
  • 131 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.